Intelligence Β· Clinical Pipeline

AstraZeneca Pipeline

All ClinicalTrials.gov programs at AstraZeneca β€” phase, modality, and trial IDs.

Programs
6

Quick answer

AstraZeneca has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. AZD1222

    AstraZeneca

    COVID-19, SARS-CoV-2

    approved mab terminated

    1 trial
  2. Dapagliflozin

    AstraZeneca

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial
  3. Durvalumab

    AstraZeneca

    Solid Tumor

    approved small molecule completed

    1 trial
  4. IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial
  5. Symbicort Turbuhaler (budesonide/formoterol) 320/9 ΞΌg

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule completed

    1 trial
  6. Symbicort Turbuhaler 160/4.5

    AstraZeneca

    Asthma

    approved small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does AstraZeneca have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs